[ad_1]
Lyfegen, which affords a platform for value-based contracting for high-cost medicine, introduced it had raised $8 million in Collection A funding.
The spherical was led by aMoon, with participation from APEX Ventures and different traders. The startup, which is headquartered in Switzerland and the U.S., affords software program that goals to assist pharma firms, payers, suppliers and medical expertise firms undertake value-based contracts. It features a library of contracts, instruments to simulate how fashions will work earlier than implementing them, and information assortment to trace efficiency and outcomes.
“We at the moment work with main authorities payers and medical health insurance firms in Europe, the U.S. and the Center East, and a few of the world’s largest pharma firms,” Girisha Fernando, CEO and founding father of Lyfegen, stated in an announcement.
“Our plan now could be to additional develop our presence within the U.S., partnering with each non-public and public healthcare insurance coverage firms. The transfer away from volume-based healthcare has by no means been extra wanted, and we’re comfortable to play an vital position within the shift to value-based contracting.”
Sensible stethoscope firm Eko obtained a $2.7 million grant from the Nationwide Institutes of Well being to develop a machine studying algorithm that detects and classifies pulmonary hypertension.
The Small Business Innovation Research (SBIR) Direct Part II grant will go towards an algorithm that makes use of phonocardiogram (PCG) and electrocardiogram (ECG) information collected by Eko’s stethoscopes to search out pulmonary hypertension, or hypertension, that impacts arteries within the lungs and the best aspect of coronary heart.
Eko has beforehand partnered with Lifespan Well being System’s Cardiovascular Institute to gather real-world PCG and ECG information that shall be a part of the algorithm’s improvement.
“The main purpose of this research is to find out whether or not an Eko algorithm based mostly on phonocardiography coupled with electrocardiography can determine the presence and severity of pulmonary hypertension when in comparison with the present gold commonplace,” stated Dr. Gaurav Choudhary, principal investigator and director of cardiovascular analysis on the Lifespan Cardiovascular Institute.
“This machine studying algorithm has the potential to be a low price, simply implementable and sustainable medical expertise that assists healthcare professionals in figuring out extra sufferers with pulmonary hypertension.”
Eko stated that is their fourth SBIR grant. The corporate not too long ago received FDA 510(k) clearance for an algorithm that detects and characterizes coronary heart murmurs in grownup and pediatric sufferers.
Halo, which affords a platform that goals to attach firms and scientists for analysis and improvement, raised $2.6 million in seed funding.
Contributors within the spherical embrace Uneven Capital Companions, Village World, AirAngels, 23andMe cofounder and CEO Anne Wojcicki, cofounder and CTO of e mail consumer Superhuman Conrad Irwin, and Rachel Hepworth, head of promoting at organizational software program firm Notion.
The platform permits biopharma, medical machine, client items and agriculture firms to submit requests for proposals for particular wants or open calls round basic analysis pursuits. Scientists can then reply with their proposals, and corporations can choose researchers for partnerships.
Halo plans to make use of the seed to rent new staff, develop new collaboration options on the platform and develop its community of scientists.
“Collaborating in R&D is simply as a lot about relationships as it’s in regards to the analysis itself. Nonetheless, firms nonetheless depend on practices that do not scale, like listening to a chat at a convention or studying a journal article. This limits companies to a handful of current relationships and pure happenstance,” Kevin Leland, founder and CEO of Halo, stated in an announcement.
“Halo connects company R&D groups instantly with scientists. By way of our platform, we engineer serendipity so firms can rapidly and simply scout for brand new applied sciences, develop their networks globally and construct relationships with scientists yr spherical.”
[ad_2]
Source link
